October - December 2009

December 15, 2009		Seattle Genetics and Millennium: The Takeda Oncology Company Announce Strategic Collaboration for Novel Late Stage Lymphoma Program Brentuximab Vedotin (SGN-35)
December 15, 2009		Takeda and Pfizer to Co-Promote Takeda's Actos® (pioglitazone HCl) for the Treatment of Type 2 Diabetes in China
December 14, 2009		TAK-085 Entered into Phase 3 Clinical Programs for Treatment of Hypertriglyceridemia in Japan
December 2, 2009		Takeda to Continue Strategic Expansion with Operations in Brazil
November 27, 2009		Takeda Pharmaceutical Company wins major British Council Arts & Business International Award for partnership with the London Symphony Orchestra
November 25, 2009		Takeda Submitted an Application for an Additional Indication for Takepron® Capsules 15 and Takepron® OD Tablet 15 in Japan for new indications regarding Prevention of NSAIDs-Associated Gastric Ulcer/Duodenal Ulcer
November 18, 2009		- Takeda Well-Being Program 2009 - "Giving Children in Long-term Treatment the Energy to Live"
November 18, 2009		TAK-438 Enters Phase II Clinical Trials for the Treatment of Reflux Esophagitis
November 13, 2009		Takeda Selected for Carbon Disclosure Leadership Index 2009
November 2, 2009		Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
October 23, 2009		Blister card for Benet® 17.5 mg tablets for the treatment of osteoporosis receivesthe Good Design Award 2009 and the Japan Packaging Contest Appropriate Packaging Award
October 20, 2009		Takeda Announces Principal Sponsorship of the Yokohama Women's Marathon
October 19, 2009		Approval of an Additional Indication of BASEN®; Prevention of Onset of Type 2 Diabetesin Patients with Impaired Glucose Tolerance
October 1, 2009		Takeda to Establish Four Sales and Marketing Subsidiaries to Expand its Operations in Mexico, Turkey and Five Other Countries in Europe
October 1, 2009		Application Submitted for Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors